Bio Green Med Solution (BGMS) Receivables - Net (2011 - 2026)
Bio Green Med Solution (BGMS) posted quarterly Receivables - Net of $1.5 million for Q1 2026, up 17.26% quarter-over-quarter from $1.3 million in Q4 2025.
Powered by 
Analysis
Bio Green Med Solution (BGMS) Receivables - Net (2011 - 2026) Analysis & Trends
Bio Green Med Solution (BGMS) has reported Receivables - Net for 10 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, changed N/A from the prior year.
- Receivables - Net improved to $1.5 million in Q1 2026 per BGMS's latest filing, from $1.3 million in the prior quarter.
- Across five years, Receivables - Net topped out at $1.5 million in Q1 2026 and bottomed at $725000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.65 Bn | 133.79 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 87.58 Bn | 79.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.74 Bn | 1.37 Bn |
| 4 | Moderna | 58.15 Bn | 53.02 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.29 Bn | 44.29 Bn | - |
| 6 | BeOne Medicines | 40.55 Bn | 35.45 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.00 Bn | 31.69 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.25 Bn | 27.42 Bn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bio Green Med Solution | 5.50 Mn | 1.71 Mn | 79,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | 725,000.00 |
| Jun 30, 2018 | 66,000.00 |
| Mar 31, 2018 | 600,000.00 |
| Jun 30, 2017 | 89,000.00 |
| Mar 31, 2017 | 879,000.00 |
| Dec 31, 2016 | 10,000.00 |
| Jun 30, 2012 | 45,000.00 |
| Dec 31, 2011 | 116,000.00 |